Abstract

The prevalence of depressive disorders in modern society is quite high, which is an important medical and social issue throughout the world. The role of psychosocial factors in the development of cardiovascular diseases, as well as the high comorbidity of cardiac pathology and depression in recent decades, are beyond doubt. Therapy for depressive disorders in cardiac patients should combine efficacy and safety, as well as ensure patient adherence to therapy. Despite the rather large number and wide availability of antidepressants, including those that are relatively safe in relation to the treatment of depression in cardiovascular pathology, there is a need to search for new depressive disorders treatment options that are even safer and more effective, especially in patients with various comorbid pathologies and concomitant therapy.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call